China
Africa
Explore chapters and articles related to this topic
The Past, Present, and Future of Digital Therapeutics
Published in Oleksandr Sverdlov, Joris van Dam, Digital Therapeutics, 2023
Sarah Cronin, Sophie Madden, Laura Ardill, Kate O'Reilly, Alette Brinth, Chandana Fitzgerald, Tess Huss
Sarah Cronin, PhD is Senior Digital Health Consultant at HealthXL. She began her career as an R&D chemist, working in early stage drug discovery at GSK. Following this, she moved into academia undertaking a PhD in organic chemistry at Trinity College Dublin which she was awarded in 2019. During this time she authored 6 papers in the area of organocatalysis. She continued her academic career as a postdoc researching novel drugs for multiple sclerosis at Trinity College Dublin. Sarah now sits on the HealthXL advisory team where she collaborates with top life sciences companies to design their digital health strategies.
Ene-Reductases in Pharmaceutical Chemistry
Published in Peter Grunwald, Pharmaceutical Biocatalysis, 2019
Many drug candidate molecules contain at least one chiral center and consequently, the development of effective asymmetric synthesis methods is essential for the pharmaceutical industry. Besides the well-established metal- and organocatalytic approaches, biocatalytic strategies are being more and more considered to install chirality. Today, the production of several blockbuster drugs such as sitagliptin (Savile et al., 2010) and Montelukast (Liang et al., 2010) has been considerably improved by switching from a purely chemical to a chemoenzymatic set-up. In the early days of industrial biocatalysis, the use of hydrolases dominated the budding discipline due to the enzymes’ high stability and ease of handling; however, significant progress in the field of enzyme engineering facilitated access to robust and easy‐to‐handle oxidoreductases and transaminases which are now established tools in the synthesis of enantiopure alcohols and amines (Bornscheuer et al., 2012). This trend is also reflected by the increasing number of patents filed for biocatalytic applications in industry (Buller et al., 2018).
Asymmetric organocatalysis in drug discovery and development for active pharmaceutical ingredients
Published in Expert Opinion on Drug Discovery, 2023
The key drawbacks of organocatalysis over the first 10 years or so were its lower reactivity compared to biocatalysis and metal-based catalysis. However, over the last 10 years, significant inroads that enhance reactivity have been made.